Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 20/20 | 0.71 |
| ▸ | PRKAB2 | O43741 | 14/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 14/20 | 0.61 |
| ▸ | PRKAA1 | Q13131 | 14/20 | 0.61 |
| ▸ | PRKAG3 | Q9UGI9 | 14/20 | 0.61 |
| ▸ | PRKAG2 | Q9UGJ0 | 14/20 | 0.61 |
| ▸ | PRKAB1 | Q9Y478 | 14/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18013671 | 1.00 | PRKAA2 (0.71) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518530 | 0.94 | PRKAA2 (0.79) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518531 | 0.94 | PRKAA2 (0.79) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518961 | 0.93 | PRKAA2 (0.64) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518960 | 0.93 | PRKAA2 (0.64) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518958 | 0.92 | PRKAA2 (0.79) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518959 | 0.92 | PRKAA2 (0.79) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518684 | 0.90 | PRKAA2 (0.73) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518685 | 0.90 | PRKAA2 (0.73) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL15164567 | 0.88 | PRKAA2 (0.91) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663496-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.